We sought to elaborate protective effects by ATX inhibition using lead compound 13 (ATX-i) in two glaucoma models of RGC degeneration, an ischemia/reperfusion (I/R) model and an experimental autoimmune glaucoma (EAG) model. Here, ENPP2 is linked to glaucoma.